Literature DB >> 18562009

Outcomes of treatment for hematogenous Staphylococcus aureus vertebral osteomyelitis in the MRSA ERA.

Daniel J Livorsi1, Naval G Daver, Robert L Atmar, Samuel A Shelburne, A Clinton White, Daniel M Musher.   

Abstract

OBJECTIVES: Hematogenous vertebral osteomyelitis is caused predominantly by Staphylococcus aureus. The rise in incidence of methicillin-resistant S. aureus (MRSA) has complicated the treatment of this infection. Our objective was to evaluate therapeutic outcomes for S. aureus vertebral osteomyelitis in a setting of high MRSA prevalence.
METHODS: We conducted a retrospective chart review of all patients who presented with S. aureus vertebral osteomyelitis over a 7-year period at 2 tertiary care hospitals in Houston, TX, USA.
RESULTS: Thirty-five patients were identified who received > or =2-week course of parenteral antibiotics and had a follow-up period of at least 12 months post-therapy. MRSA was responsible for 20 (57%) cases. Mean duration of total antibiotic therapy was 61.4 days. The overall relapse rate was 14%. At 12 months post-therapy, 86% patients were cured. The one factor significantly associated with relapse was presence of undrained abscesses (p=0.04).
CONCLUSIONS: When the mean duration of effective antibiotic therapy was 60 days, cure rates for S. aureus vertebral osteomyelitis exceeded 80%. Drainage of all associated abscesses correlated with a significantly higher rate of cure.

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 18562009     DOI: 10.1016/j.jinf.2008.04.012

Source DB:  PubMed          Journal:  J Infect        ISSN: 0163-4453            Impact factor:   6.072


  16 in total

1.  Therapeutic outcomes of pyogenic vertebral osteomyelitis requiring spinal instrumentation.

Authors:  Ki-Ho Park; Oh-Hyun Cho; In-Gyu Bae; Mi Suk Lee
Journal:  Antimicrob Agents Chemother       Date:  2014-11       Impact factor: 5.191

2.  Susceptibility Pattern of Microorganisms Isolated by Percutaneous Needle Biopsy in Nonbacteremic Pyogenic Vertebral Osteomyelitis.

Authors:  Sophie Desoutter; Jean-Philippe Cottier; Idir Ghout; Bertrand Issartel; Aurélien Dinh; Arnaud Martin; Robert Carlier; Louis Bernard
Journal:  Antimicrob Agents Chemother       Date:  2015-10-05       Impact factor: 5.191

Review 3.  Systemic antibiotic therapy for chronic osteomyelitis in adults.

Authors:  Brad Spellberg; Benjamin A Lipsky
Journal:  Clin Infect Dis       Date:  2011-12-12       Impact factor: 9.079

Review 4.  Spinal and paraspinal pneumococcal infections-a review.

Authors:  D M Siddiq; D M Musher; R O Darouiche
Journal:  Eur J Clin Microbiol Infect Dis       Date:  2014-01-31       Impact factor: 3.267

5.  Can we predict favourable quality of life after surgically treated vertebral osteomyelitis? Analysis of a prospective study.

Authors:  A Yagdiran; C Otto-Lambertz; B Sondermann; A Ernst; D Jochimsen; R Sobottke; J Siewe; P Eysel; N Jung
Journal:  Arch Orthop Trauma Surg       Date:  2022-03-31       Impact factor: 3.067

6.  The epidemiology of hematogenous vertebral osteomyelitis: a cohort study in a tertiary care hospital.

Authors:  Kavita P Bhavan; Jonas Marschall; Margaret A Olsen; Victoria J Fraser; Neill M Wright; David K Warren
Journal:  BMC Infect Dis       Date:  2010-06-07       Impact factor: 3.090

7.  De novo methicillin-resistant Staphylococcus aureus vs. methicillin-sensitive Staphylococcus aureus infections of the spine, similar clinical outcome, despite more severe presentation in surgical patients.

Authors:  Basem Ishak; Amir Abdul-Jabbar; Gregory B Moss; Emre Yilmaz; Alexander von Glinski; Sven Frieler; Andreas W Unterberg; Ronan Blecher; Juan Altafulla; Jeffrey Roh; Robert A Hart; Rod J Oskouian; Jens R Chapman
Journal:  Neurosurg Rev       Date:  2020-08-27       Impact factor: 3.042

8.  Progressive flaccid paraparesis with albuminocytologic dissociation: It's not always Gullain-Barre syndrome.

Authors:  Dimitrios Nouvakis; Konstantinos S Natsis; Antonia Tsika; Georgia Kourtesi; Evangelos Papamichalis; Harilaos Mourtzinos
Journal:  J Spinal Cord Med       Date:  2018-06-25       Impact factor: 1.985

9.  Comparison of clinical features and outcomes of staphylococcus aureus vertebral osteomyelitis caused by methicillin-resistant and methicillin-sensitive strains.

Authors:  Shinichi Inoue; Tokuhide Moriyama; Yutaka Horinouchi; Toshiya Tachibana; Fumiaki Okada; Keishi Maruo; Shinichi Yoshiya
Journal:  Springerplus       Date:  2013-06-27

Review 10.  Preclinical models of vertebral osteomyelitis and associated infections: Current models and recommendations for study design.

Authors:  Kieran Joyce; Daisuke Sakai; Abhay Pandit
Journal:  JOR Spine       Date:  2021-03-02
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.